Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.
Projects include upgrades to existing analytical services, the installation of new equipment, including reactors, filter dryers, and distillation units.
Detailing bioanalytical approaches to investigating antibody-drug conjugates (ADCs) along with recommendations for drug sponsors currently developing them.
Dr. Maotian Zhou, Principal Scientist - DMPK Services, WuXi AppTec10.03.22